NASDAQ · Biotechnology · USD
MetaVia Inc. (MTVA) Stock Analysis
MetaVia Inc. (MTVA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
MTVA Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.29
- Previous Close
- $1.29
- Day's Range
- 1.29–1.37
- 52-Week Range
- 0.97–14.85
- Volume
- 42.15K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.96
Valuation
- Market Cap
- $8.83M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −3.65
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$12.97M
- Shares Outstanding
- 6.59M
- 1-Year Return
- −87.82%
Dividend and dates
- Avg Volume
- 77.28K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, MTVA closed at $1.34, −87.82% over 1 year.
MetaVia Inc. (MTVA) has a market capitalization of $8.83M.
In fiscal 2025, MTVA reported revenue of $0.00.
MTVA Stock Return by Calendar Year
MetaVia Inc. (MTVA) 10-year return: what $10,000 became
- 1 year
- $10,000 $1,218
- −87.82%
- 5 years
- $10,000 $3
- −99.97%
- 10 years
- $10,000 $0.02
- −99.9998%
If you had invested $10,000 in MetaVia Inc. (MTVA) 10 years ago, at the close on October 21, 2016, it would have been worth $0.02 at the close on October 21, 2026: −99.9998% in total, −73.12% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −84.09% |
| 2025 | −62.29% |
| 2024 | −45.09% |
| 2023 | −35.64% |
| 2022 | −98.04% |
| 2021 | −76.76% |
| 2020 | −40.00% |
| 2019 | −56.79% |
| 2018 | −89.80% |
| 2017 | +1.34% |
| 2016 (partial year) | −11.71% |
As of October 21, 2026.
MTVA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$12.97M | — |
| 2024 | $0.00 | −$27.59M | — |
| 2023 | $0.00 | −$12.47M | — |
| 2022 | $0.00 | −$13.97M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$13.71M | −$12.97M | — |
| 2024 | $0.00 | — | −$28.81M | −$27.59M | — |
| 2023 | $0.00 | — | −$15.89M | −$12.47M | — |
| 2022 | $0.00 | — | −$11.42M | −$13.97M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
YahooMTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction
YahooMetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
YahooMetaVia Q2 EPS $(0.90) Misses $(0.82) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B